Literature DB >> 27298419

Androgen Deprivation Therapy and Alzheimer's Disease.

Michael Froehner1, Manfred P Wirth2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27298419      PMCID： PMC5019751          DOI： 10.1200/JCO.2016.66.4441

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Authors:  Edward M Messing; Judith Manola; Jorge Yao; Maureen Kiernan; David Crawford; George Wilding; P Anthony di'SantAgnese; Donald Trump
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

Review 2.  Alzheimer's disease.

Authors:  Clive Ballard; Serge Gauthier; Anne Corbett; Carol Brayne; Dag Aarsland; Emma Jones
Journal:  Lancet       Date:  2011-03-01       Impact factor: 79.321

3.  Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease.

Authors:  Anthony V D'Amico; Michelle H Braccioforte; Brian J Moran; Ming-Hui Chen
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jan-Mar       Impact factor: 2.703

4.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

5.  Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.

Authors:  Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Joel T Dudley; Nicholas J Leeper; Nigam H Shah
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544
  5 in total
  1 in total

1.  Reply to R.L. Bowen et al, M. Froehner et al, J.L. Leow et al, and C. Brady et al.

Authors:  Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Joel T Dudley; Nicholas J Leeper; Nigam H Shah
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.